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E-mail address: claudiu.supuran@unifi.it (C.T. SupuThe Gram-positive bacterium Streptococcus pneumoniae is a human respiratory tract pathogen that con-
tributes significantly to global mortality and morbidity. It was recently shown that this bacterial patho-
gen depends on a conserved b-carbonic anhydrase (CA, EC 4.2.1.1) for in vitro growth in environmental
ambient air and during intracellular survival in host cells. Hence, it is to be expected that this pneumo-
coccal carbonic anhydrase (PCA) contributes to transmission and pathogenesis of the bacterium, making
it a potential therapeutic target. In this study, purified recombinant PCA has been further characterized
kinetically and for inhibition with a series of inorganic anions and small molecules useful as leads. PCA
has appreciable activity as catalyst for the hydration of CO2 to bicarbonate, with a kcat of 7.4  105 s1 and
kcat/Km of 6.5  107 M1 s1 at an optimum pH of 8.4. Inorganic anions such as chloride, bromide, iodide,
cyanate, selenocyanate, trithiocarbonate, and cyanide were effective inhibitors of PCA (KIs of 21–98 lM).
Sulfamide, sulfamic acid, phenylboronic, phenylarsonic acid, and diethyldithiocarbamate showed inhibi-
tion constants in the low micromolar/submicromolar range (KIs of 0.61–6.68 lM), whereas that of the
sulfonamide acetazolamide was in the nanomolar range (KIs 89 nM). In conclusion, our results show that
PCA can effectively be inhibited by a range of molecules that could be interesting leads for obtaining more
potent PCA inhibitors. PCA might be a novel target for designing antimicrobial drugs with a new mech-
anism of action.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
The respiratory tract bacterium Streptococcus pneumoniae, or
pneumococcus, is one of the most frequently encountered patho-
gens in humans, and is responsible for the death of approximately
1 million children under the age of five each year.1 It causes various
infections, such as meningitis, septicemia, otitis media, sinusitis,
and pneumonia. S. pneumoniae is a facultative anaerobe capable
to adapt to the different environments it encounters during trans-
mission, host colonization, and disease. An important variable in
these niches is the level of carbon dioxide (CO2), which could be
as low as 0.038% in environmental ambient during transmission
and over 5% in the lungs and infected tissues. It is known for a long
time that the complete depletion of environmental CO2 inhibits
pneumococcal growth,2 suggesting that CO2 needs to be retained
inside S. pneumoniae to support cellular processes. Recently, one
of our groups showed that a mutant in the single, highly conserved
pneumococcal b-carbonic anhydrase (PCA) renders in vitro growth
of S. pneumoniae dependent on elevated CO2-levels or on supple-ll rights reserved.
: 39 055 4573385.
ran).mentation with unsaturated fatty acids. These observations linked
PCA-mediated CO2-fixation to fatty acid metabolism, and sug-
gested that PCA is important for pneumococcus to cope with
changes in nutrient availability during niche transition.3 Further-
more, we also observed a reduced survival of S. pneumoniae pca
mutant strains inside host cells suggesting that PCA is also needed
for pneumococcal adaptation to pathogenesis-related processes.3
Similar to PCA, carbonic anhydrases (CAs, EC 4.2.1.1) of various
microbial pathogens have been implicated in cell survival and path-
ogenesis.4,5 It is therefore not surprising that CAs are considered as
an emerging class of potential therapeutic targets also for the design
of antiinfectives.5 CAs, which catalyze the reversible hydration of
carbon dioxide to bicarbonate (CO2 + H2OM HCO3
 + H+), are an-
cient enzymes that were previously shown to be crucial in the regu-
lation of acid–base balance in organisms all over the phylogenetic
tree.4–11 In addition, CAs participate in many other physiological
processes, such as lipogenesis, gluconeogenesis, ureagenesis, bone
resorption, production of body fluids, and transport of CO2 and
HCO3
, tumorigenesis, etc. (in mammals),5,8 as well as CO2 concen-
trating mechanisms and photosynthesis (in plants, algae, some
bacteria, and diatoms).6,7 Five genetically distinct classes of these
enzymes have been identified so far: the a, b, c, d, and f-CAs.4–8
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ious organisms all over the phylogenetic tree but absent in humans.4
The identification and characterization of b-CAs in a number of hu-
man pathogens, such as fungi/yeasts (e.g., Candida species, Crypto-
coccus neoformans, and Saccharomyces cerevisiae),9–12 and bacteria
(e.g., Brucella suis, Helicobacter pylori, Mycobacterium tuberculosis,
and Haemophilus influenzae),13–18 has already lead to novel antimi-
crobial compounds, with a new mechanism of action, as recently
shown for a b-CA from B. suis,18 or for the enzymes from H. pylori.13
Continuing our interest in finding and characterizing members
of the b-CA family in pathogenic organisms for the development
of novel antimicrobial compounds, we report the kinetic character-
ization PCA from S. pneumoniae. We also report the first inhibition
study of this enzyme with inorganic anions, various small com-
pounds known to target the metal ion in metalloenzymes like
CAs, and the broad-range CA inhibitory compound acetazolamide
(AZA).
2. Results and discussion
2.1. Catalytic activity of PCA
In the previous work3 the catalytic activity for the physiologic
reaction, that is, CO2 hydration to bicarbonate and protons, has
been evidenced for PCA, but the kinetic parameters were not deter-
mined. Thus, we investigate here in detail the properties of this
new and interesting representative of the b-CA class.
In Figure 1, we have aligned the PCA protein sequence with var-
ious b-CAs fromarchaeal, bacterial or fungal origin.7,9,12–18 Itmay be
observed that PCAhas all the amino acids residues typical of catalyt-
ically active b-CAs, which are involved in the catalytic cycle of this
class of enzymes:4 (i) the Zn(II) binding residues Cys36, His89, and
Cys92;4,5,11 and (ii) the Asp38-Arg40 catalytic dyad, involved in
the opening/closing of the active site.14 Indeed, unlike a-, c-, and
d-CAs, for which the Zn(II) is coordinated by three His residues and
a water molecule/hydroxide ion, in the case of the b-class CAs the
metal ion coordination is more complicated, being generally
achieved by one His and two Cys residues.4,5,11,14 However, some
b-class enzymes have four protein zinc ligands, that is, one His,
two Cys, and one Asp coordinated to Zn(II).14 For these enzymes
no water coordinated to the metal ion is present at pH values <8,
as shown in an excellent crystallographic work from Jones’ group
on the mycobacterial enzymes Rv3558c and Rv1284.14 However,
at pH values >8, a conserved Arg residue in all b-CAs investigated
so far (belonging to the above-mentioned catalytic dyad)14 makes
a salt bridgewith the Asp coordinated to Zn(II), liberating the fourth
Zn(II) coordination position, which is then occupied by an incoming
water molecule/hydroxide ion, acting thereafter as nucleophile in
catalyzing CO2 hydration to bicarbonate.14
Based only on the amino acid sequence, it is however impossi-
ble to predict whether PCA will have a open or closed active site. In
the open form, Cys36, Cys92, His89, and a catalytic water mole-
cule/hydroxide ion would coordinate the Zn(II) ion, allowing the
enzyme to be active over a broad pH-range. In the closed form,
Aps38 would additionally coordinate to the Zn(II) ion as well,
thereby replacing the water molecule/hydroxide ion needed for
the catalytic activity. Only at pH values >8, when the conserved
Arg40 residue makes a salt bridge with Asp38, the fourth Zn(II)
coordination position may be available for the catalytic water mol-
ecule/hydroxide ion.14 To test if PCA has an open or closed active
site, we accurately measured its catalytic activity at different pH
values (Table 1). In Table 1 we show that the catalytic activity of
PCA is absent at pH of 6.5 and 7.5, being very low at pH 8, and stea-
dily increasing at higher pH values (8.2 and 8,4), which implies
that PCA probably has a closed active (with Asp38 is coordinated
to the metal ion) at pH values under 8. It should be noted thatthe optimum pH for the hydration of CO2 correlates very well
physiological conditions in which PCA is optimally expressed.
Expression of the pca gene is induced in the pneumococcal X-sta-
te,19a which is a physiological condition that allows for genetic
transformation, biofilm formation, and an adequate response to
environmental stress.19b,c During the X-state, the intracellular pH
in S. pneumoniae rises to about pH 8.3 as result of increased glycol-
ysis and sodium (Na+) fluxes.19d,e Whether PCA is needed in these
conditions to compensate for further alkalinization of the cytosol,
providing HCO3
 to match with intracellular levels of Na+, or to
sustain metabolic pathways needed in the X-state remains to be
investigated. It should be anyhow mentioned that the CO2 hydrase
activity of PCA and of any other CA belonging to the various en-
zyme classes is increasing with the pH as the alkaline medium is
favorable to the formation of the zinc hydroxide species of the en-
zyme. However at pH values >8.5 the uncatalyzed CO2 hydrations
starts to drastically compete with the reaction catalyzed by the en-
zymes. These are the two reasons why we did not measure PCA
catalytic activity at pH values higher than 8.4.
Next, we zoomed in at the PCA kinetic parameters for the CO2
hydration reaction at pH 8.4, and compared it to that ofa-CAs of hu-
man (h) origin (hCAI and hCAII) and b-CAs from the archaeon Met-
hanobacterium thermoautotrophicum (Cab)20 and the pathogenic
fungus C. neoformans (Can2)11 investigated earlier (Table 1). These
data showed that PCA has a significant activity as catalyst for the
conversion of CO2 to bicarbonate, with a kcat of 7.4  105 s1, and
kcat/Km of 6.5  107 M1 s1. Thus, PCA is a better catalyst for the
physiological reaction than the human isoforms hCA I or the other
twob-class enzymeswithwhich it has beencompared in thepresent
work.
2.2. Inhibition of PCA with inorganic anions and other small
molecules
Since CAs bind HCO3
, a substrate and inhibitor of these en-
zymes,4–8 inorganic anions do have a profound impact on their cat-
alytic activity. Indeed, many classes of CAs, including the b one,
have been investigated for their interaction with anion inhibi-
tors,5,6,8,16,20–23 which, as in solution (e.g., cyanide, thiocyanate,
azide, and other such metal complexing species), directly bind to
the metal ion from the enzyme active site, in tetrahedral or trigonal
bipyramidal geometry of the Zn(II) ion.5,6,8,11
Inhibition data of PCAwith small inorganic anionswas compared
with inhibition data of the a-CA isoforms hCA I and II (Table 2), as
well as the b-class enzymes Cab and Can2 reported earlier.12,19 Sim-
ple inorganic anions, including the physiological ones (such as chlo-
ride, bicarbonate, carbonate, and sulfate), as well as ‘metal poisons’
(cyanide, cyanate, thiocyanate, azide, hydrogen sulfide, bisulfite, ni-
trite, etc.) or anions with less affinity for metal ions in solution (tet-
rafluroborate, perchlorate, nitrate, fluoride, and heavier halides,
among others) were included in this study. On the other hand, less
investigated inorganic anions, such as stannate(IV), selenate(VI),
tellurate(VI), perosmate(VIII), persulfate, pyrophosphate(V), pyro-
vanadate(V), tetraborate, perrhenate(VII), perrutenate(VII),
persulfate, selenocyanate, iminodisulfonate, fluorosulfate, and tri-
thiocarbonate were also included in this study, as they recently
allowedus todiscover newzinc-binding groups for designingpotent
a-CA inhibitors.22
Similar to all other a- and b-CAs investigated so far, PCA was
not sensitive to inhibition by perchlorate (KI > 200 mM). Also sul-
fate was not very inhibitory (inhibition constant of 4.15 mM), but
fluoride, thiocyanate, azide, carbonate, bicarbonate, nitrate, nitrite,
hydrogen sulfide, bisulfite, pyrophosphate, and tetraborate were
weak inhibitors, with KIs in the range of 0.32–0.85 mM. Halides
other than fluoride, cyanate, and cyanide, were more potent inhib-
itors of PCA, with KIs in the range of 41–98 lM. Thus, for the ha-
Figure 1. Alignment of S. pneumoniae PCA, M. tuberculosis Rv1284, M. thermoautotrophicum Cab, C. neoformans Can2, and M. tuberculosis Rv3588c amino acid sequences. The
three zinc ligands (Cys36, His89, and Cys92, PCA numbering) are evidenced in blue (and the ‘Z’ sign) whereas the other conserved amino acid residues between the five b-CAs
are evidenced by an asterisk. The two conserved residues Asp38, Arg40, thought to be involved in the b-CA catalytic cycle are shown in red. Amino acids where conserved
substitutions were identified are represented with the ‘:’ sign, while semi-conserved substitutions are represented by the ‘.’ symbol. Identity and similarity of the five b-CAs to
PCA are given in parentheses.
Table 1
Kinetic parameters for the CO2 hydration reaction catalyzed by the human cytosolic
isozymes hCA I and II (a-class CAs) at 20 C and pH 7.5 in 10 mM HEPES buffer and
20 mM Na2SO4, and the b-CAs Cab (from M. thermoautotrophicum), Can2 (from
C. neoformans), and PCA (S. pneumoniae), respectively, measured at 20 C, pH 5.6–8.4
in 10 mM Tris, HEPES or TAPS buffers and 20 mM NaClO421
Isozyme Activity level kcat (s1) kcat/Km (M1 s1) pH
hCA Ia Moderate 2.0  105 5.0  107 7.5
hCA IIa Very high 1.4  106 1.5  108 7.5
Cabb Low 3.1  104 1.8  106 8.4
Can2b Moderate 3.9  105 4.3  107 8.4
PCAc Inactive 0 0 6.5
PCAc Inactive 0 0 7.5
PCAc Very low 1.1  104 1.9  105 8.0
PCAc Moderate 6.1  105 5.4  107 8.2
PCAc Moderate 7.4  105 6.5  107 8.4
a,b Data from Refs. 4,11,20.
c This work.
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then slightly decreases again for iodide. This observation is very
relevant, as, especially, chlorides are commonly used for buffer
preparation. In fact, our first batch of purified PCA enzyme was
only poorly active as a consequence of the presence of 50 mM
Tris–HCl in the final preparation (data not shown).3 It is also inter-esting to note that cyanide and cyanate are much more inhibitory
than thiocyanate, although for other b-CAs, such as Cab and Can2,
thiocyanate was a better inhibitor compared to cyanate. Cyanide
showed weak inhibition of the b-CAs Cab and Can2 (KIs of 13.56–
27.8 mM) while being an effective PCA inhibitor (KI of 41 lM).
The less investigated inorganic anions incorporating heavy metal
ions, as well as persulfate, peroxydisulfate, selenocyanate, fluoro-
sulfate, and trithiocarbonate also showed significant PCA inhibi-
tory activity, with inhibition constants in the range of 21–66 lM
(Table 2). In this series of inorganic anions selenocyanate and tri-
thiocarbonate were the best PCA inhibitors, with KIs of 21–
22 lM. As the last anion incorporates a moiety amenable to the
development of organic inhibitors, as already showed earlier,21
we investigated diethyldithiocarbamate, a compound incorporat-
ing the CS2
 moiety present in trithiocarbonate as PCA inhibitor,
together with several lead compounds that could serve as basis
for the design of even more effective inhibitors (Table 3). Sulfam-
ide, sulfamic acid, phenylboronic acid, and phenylarsonic acid are
potent zinc-binding molecules that were previously shown to tar-
get several CAs in the low micromolar range.24,25
Data of Table 3 show that PCA was also inhibited in the low
micromolar range by these compounds, with KIs in the range of
0.61–28.1 lM. Relevant for further research is the fact that phenyl-
boronic acid and phenylarsonic acid inhibited rather well PCA and
the other investigated b-CAs but not the human isoforms hCA I and
Table 2
Inhibition constants of anionic inhibitors against isozymes hCA I, and II (a-CA class),
and b-isozymes Cab (from the archaeon M. thermoautotrophicum) as well as Can2
(from C. neoformans) and PCA (from S. pneumoniae), for the CO2 hydration reaction, at
20 C21
Inhibitora KIb (mM)
hCA Ic hCA IIc Cabd Can2d PCAe
F >300 >300 >1000 0.86 0.85
Cl 6 200 152 0.92 0.052
Br 4 63 42.1 1.00 0.046
I 0.3 26 13.2 1.11 0.054
CNO 0.0007 0.03 11.2 1.01 0.098
SCN 0.2 1.60 0.52 0.94 0.38
CN 0.0005 0.02 27.8 13.56 0.041
N3
 0.0012 1.51 55.7 0.73 0.35
HCO3
 12 85 44.9 0.75 0.33
CO3
 15 73 9.6 0.60 0.53
NO3
 7 35 7.8 0.92 0.39
NO2
 8.4 63 44.8 0.96 0.66
HS 0.0006 0.04 0.70 0.60 0.35
HSO3
 18 89 45.1 0.71 0.57
SnO3
2 0.57 0.83 nt nt 0.066
SeO4
2 118 112 nt nt 0.044
TeO4
2 0.66 0.92 nt nt 0.049
OsO5
2 0.92 0.95 nt nt 0.060
S2O7
2 0.99 0.97 nt nt 0.048
P2O7
4 25.77 48.50 nt nt 0.45
V2O7
4 0.54 0.57 nt nt 0.038
B4O7
2 0.64 0.95 nt nt 0.32
ReO4
 0.110 0.75 nt nt 0.039
RuO4
 0.101 0.69 nt nt 0.036
S2O8
2 0.107 0.084 nt nt 0.046
SeCN 0.085 0.086 nt nt 0.022
FSO3
 0.79 0.46 nt nt 0.060
CS3
2 0.0087 0.0088 nt nt 0.021
SO4
2 63 >200 >200 0.86 4.15
ClO4
 >200 >200 >200 >200 >200
a As sodium salt.
b Errors were in the range of 3–5% of the reported values, from three different
assays.
c,d From Refs. 12,20.
e This work.
Table 3
Inhibition constants of small molecule compounds against isozymes hCA I and II
(a-CA class), and b-isozymes Cab (from the archaeonM. thermoautotrophicum) as well
as Can2 (from C. neoformans) and PCA (from S. pneumoniae), for the CO2 hydration
reaction, at 20 C21
Inhibitora KIb (lM)
hCA Ic hCA IIc Cabd Can2d PCAe
NHðSO3Þ22 0.31 0.76 nt nt 28.1
H2NSO2NH2 0.31 1.13 103 0.99 4.25
H2NSO3H 0.021 0.39 44.0 8.22 6.68
Ph-B(OH)2 58.6 23.1 0.20 0.81 6.47
Ph-AsO3H2 31.7 49.2 0.33 0.87 5.86
Et2NCS2
 0.79 3.1 nt nt 0.61
AZA 0.250 0.012 12.1 0.0105 0.089
a As sodium salt.
b Errors were in the range of 3–5% of the reported values, from three different
assays;
c,d From Refs. 5,12,20.
e This work.
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(KIs of 4.25–6.68 lM), whereas iminodisulfonate was the least
effective one among this small group of molecules, with an inhibi-
tion constant of 28.1 lM (Table 3). However diethyldithiocarba-
mate was a very effective PCA inhibitor, with a KI of 0.61 lM,
whereas it has a roughly 5 times less affinity for hCA II, the phys-iologically dominant human isoform. Thus, this simple molecule
may be considered as an excellent lead for developing better PCA
inhibitors.
The best inhibitor for PCA investigated so far, appeared to be the
clinically used sulfonamide acetazolamide, 5-acetamido-1,3,4-thia-
diazole-2-sulfonamide (AZA). Unsubstituted sulfonamide inhibitors
are known to bind with high affinity only to CAs.5 AZA showed
efficient binding to the pneumococcal enzyme, with a KIs of 89 nM
(Table 3), which is better than the KIs of the slow human isoform
hCA I (250 nM), but higher than that of the physiologically dominant
hCA II, which is inhibitedwith a KI of 12 nM. Furthermore, inhibition
of other b-CAs with this sulfonamide are quite variable, with their
archeal enzyme Cab having only micromolar affinity for the com-
pound (KI of 12.1 lM), whereas the fungal one Can2 showing nano-
molar affinity (KI of 10.5 nM).11 Interestingly, this data differ from
the previous report3 in which AZA and ethoxzolamide (EZA) were
shown to be unable to inhibit PCA (in vitro).3 However, in that study
we were unaware of the inhibitory effect of chloride (present in the
buffer solution), which might have interfered with the readout of
our assays.3 Still, preliminary in vivo pneumococcal growth
inhibition experiments with AZA and EZA did not render the wild
type strain dependent on CO2-enriched medium (data not shown).
This demonstrates that additional work on sulfonamides and other
lead molecules with increased power to penetrate through the
bacterial cell envelope as PCA inhibitors is a requisite for the
successful use of this approach as a therapeutic tool to fight pneu-
mococcal infection.2.3. Phylogenetic analysis
PCA belongs to the b-CA class, which is a very divergent class of
proteins, compared for example with the a-CAs.4 Interestingly, the
PCA gene that is present in the genomes of all S. pneumoniae strains
available in the public databases and is very conserved (data not
shown). This suggests that the gene is essential for pneumococcal
dispersal throughout the population, and that effective PCA inhib-
itors might target most if not all pneumococcal strains. A phyloge-
netic tree build from an alignment of the amino acid sequences of
b-CAs from various other bacterial, archeal, fungal, yeast, and nem-
atode species (Fig. 2), revealed that PCA has only few close homo-
logues. Pneumococcal CA is in the same phylogenetic branch as
CAs of related streptococcal species, such as Streptococcus pyogenes.
Besides, it clusters in the same clade4 as one type of CAs found in
Mycobacterium and Candida species. This suggests that inhibitors
that were recently designed for the M. tuberculosis Rv1284 CA,27
could be effective against PCA as well.3. Conclusion
The b-CA from the bacterial pathogen Streptococcus pneumoniae
was shown to be an efficient catalyst for the hydration of CO2 to
bicarbonate with an optimum pH at 8.4. These characteristics are
physiologically relevant, and helpful to determine the precise role
of this protein for growth and survival of this respiratory tract
pathogen during transmission and disease. The inhibition profile
for PCA was different from that of other a- and b-class CAs inves-
tigated earlier for their interactions with anions and similar small
molecule inhibitors. It is thus envisageable that stronger PCA
inhibitors can be detected by using as lead molecules the most po-
tent zinc-binding groups evidenced here (trithiocarbonate, seleno-
cyanate, dithiocarbamates, and sulfonamides) and by exploring a
larger array of sulfonamides. Work is in progress in these laborato-
ries to assess a large number of such derivatives to detect inhibi-
tors with possible in vivo use.
Figure 2. Phylogenetic tree of relevant b-class carbonic anhydrase proteins. The amino acid sequences of the selected b-CAs were imported in the MEGA program26 and
aligned by ClustalW. Phylogeny was calculated by the MEGA program’s neighbor joining method with the poisson substitution model and a gamma distribution parameter of
2.0. Displayed is the consensus tree after 1000 bootstrap replicates. The b-CAs used for alignment in Fig. 1 are indicated bold. The bar scale indicates the expected number of
amino acid replacements per site.
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4.1. Chemistry
Inorganic sodium salt of anions from Tables 2 and 3, buffers,
sulfamide, sulfamic acid, phenylarsonic acid, phenylphosphonic
acid, sodium diethyldithiocarbamate, and other reagents were
the highest grade purity available, from Sigma–Aldrich (Milan,
Italy).
4.2. PCA cloning, preparation, and purification
Production and purification of PCA as a glutathione S-transfer-
ase fusion protein (GST-PCA) was performed as earlier described3
with only minor modifications. Briefly, an Escherichia coli BL21
(pWA4) culture was grown in 2 Luria Bertani broth at 37 C to
an optical density at 600 nm of 0.6–0.8, shifted to room tempera-
ture, and induced for GST-PCA production by addition of 0.1 mMisopropyl-b-D-thiogalactopyranoside. After 4 h, cells resuspended
in lysis buffer (50 mM Tris–HCl pH 7.5, 300 mM NaCl, 0.5 mM
dithiothreitol, 1.5 mM MgCl2, 0.2 mM EDTA, 1% Triton X-100) with
1 protease inhibitor mixture (Complete Mini; Roche Applied Sci-
ence), lysed by sonication, and GST-PCA was affinity purified from
the soluble fraction with Glutathione Sepharose 4 Fast Flow beads
(GE Healthcare) at 4 C. Eluted GST-PCA was dialyzed against
10 mM Tris–HCl pH 7.5. The protein concentration in the solution
was determined with a BCA Protein Assay Kit (Pierce).3
4.3. CA activity and inhibition measurements
An Applied Photophysics (Oxford, UK) stopped-flow instrument
has been used for assaying the CA-catalyzed CO2 hydration activity
by the method of Khalifah.21 Phenol red or o,o0-phenanthroline (at
a concentration of 0.2 mM) have been used as indicators, working
at the absorbance maximum of 557 nm and 554, respectively, with
10–20 mM HEPES (pH 7.5, for a-CAs) or Tris, HEPES or TAPS (pH
248 P. Burghout et al. / Bioorg. Med. Chem. 19 (2011) 243–2485.6–8.4 for b-CAs) as buffers, and 20 mM Na2SO4 (for a-CAs) or 10–
20 mM NaClO4—for b-CAs (for maintaining constant the ionic
strength), following the initial rates of the CA-catalyzed CO2 hydra-
tion reaction for a period of 10–100 s.21 The CO2 concentrations
ranged from 1.7 to 17 mM for the determination of the kinetic
parameters and inhibition constants. For each inhibitor, at least
six traces of the initial 5–10% of the reaction have been used for
determining the initial velocity. The uncatalyzed rates were deter-
mined in the same manner and subtracted from the total observed
rates. Stock solutions of inhibitor (10 mM) were prepared in dis-
tilled–deionized water and dilutions up to 0.01 lM were done
thereafter with distilled–deionized water. Inhibitor and enzyme
solutions were preincubated together for 15 min at room temper-
ature prior to assay, in order to allow for the formation of the E–I
complex. The inhibition constants were obtained by non-linear
least-squares methods using PRISM 3, whereas the kinetic param-
eters for the uninhibited enzymes from Lineweaver–Burk plots, as
reported earlier,11–13 and represent the mean from at least three
different determinations.
4.4. Alignment of protein sequences and phylogenetic analysis
The amino acid sequences of the selected b-CAs were imported
in the MEGA program26 and aligned by ClustalW. Phylogeny was
calculated by the MEGA program’s neighbor joining method with
the poisson substitution model and a gamma distribution parame-
ter of 2.0. Displayed is the consensus tree after 1000 bootstrap rep-
licates. The b-CAs used for alignment in Figure 1 are indicated bold.
The bar scale indicates the expected number of amino acid replace-
ments per site.
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